Meeting
2021 ASCO Annual Meeting
V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.
Authors
Laura Agresta
Michigan State University College of Human Medicine, East Lansing, MI
Laura Agresta , Maureen Megan O'Brien , Eric Justin O'Brien , Robin Elizabeth Norris , Erin Haag Breese , Karen Cristly Burns , Benjamin Mizukawa , Thomas D Ryan , Pankaj B Desai , A.a. Vinks , H. Leighton Grimes , Michael Absalon , John Peter Perentesis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03826992
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7052)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7052
Abstract #
TPS7052
Poster Bd #
Online Only
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2018 ASCO Annual Meeting
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
First Author: Thomas Alexander
Poster
2023 ASCO Annual Meeting
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
First Author: Jianxiang Wang
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2022 ASCO Annual Meeting
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).
First Author: Farhad Ravandi